Gracell Biotechnologies Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GRCL research report →
Companywww.gracellbio.com
Gracell Biotechnologies Inc. , a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia.
- CEO
- Wei Cao BM,
- IPO
- 2021
- Employees
- 314
- HQ
- Suzhou, CN
Price Chart
Valuation
- Market Cap
- $197.97M
- P/E
- -1.55
- P/S
- 0.00
- P/B
- 0.69
- EV/EBITDA
- -0.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -37.93%
- ROIC
- -39.90%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-607,509,000 · -30.40%
- EPS
- $-44.85 · -26.69%
- Op Income
- $-624,658,000
- FCF YoY
- -907.12%
Performance & Tape
- 52W High
- $10.44
- 52W Low
- $1.40
- 50D MA
- $9.13
- 200D MA
- $5.01
- Beta
- -0.34
- Avg Volume
- 1.46M
Get TickerSpark's AI analysis on GRCL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GRCL Coverage
We haven't published any research on GRCL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GRCL Report →